Eisai projects Leqembi revenue to reach ¥1.6T by FY33 with early and pre-clinical AD indications. As of January, Leqembi reached just 2K patients in US versus target of reaching 10K patients by March.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.